Investment
Features
FeesSafety
Academy
More
Pluang+

Compare BioNano Genomics Inc (BNGO) vs Cassava Sciences Inc (FLNA) Price & Performance

BioNano Genomics IncTrade
Cassava Sciences IncTrade

Price performance (Past 24H)

Key statistics

BioNano Genomics Inc vs Cassava Sciences Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Cassava Sciences Inc trades at $0.97 (market cap $47.75M). The key difference: Cassava Sciences Inc is far larger — about 3.5× BioNano Genomics Inc's market cap. Which is the better fit depends on your goals.

BNGOFLNA
Market Cap
$13.66M$47.75M
Sector
HealthHealth
52-Week High
$4.92$4.64
52-Week Low
$1.06$0.87
Enterprise Value
$16.26M-$34.93M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

Cassava Sciences Inc

FLNA is trading at $0.9401, down 5.74% on the day, with a bearish technical signal from moving averages. The company shows consistent quarterly earnings beats but remains unprofitable with negative ROE of -55.79% and negative cash flow. Analyst sentiment is positive with 67% buy ratings, though the stock faces fundamental challenges with ongoing operational losses.

The outlook remains challenged by persistent losses and negative cash flow, though recent earnings beats and strong analyst support provide potential upside. Key risks include the company's ability to achieve profitability and sustain operations given current burn rate. The biotechnology focus on TSC-related epilepsy represents both opportunity and execution risk.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO

About Cassava Sciences Inc

Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease

Read more on FLNA